| Document |
Document Title |
|
WO/2023/175573A1 |
The invention relates to once-a-day pharmaceutical compositions comprising a fixed dose combination of a β-blocker or a pharmaceutically acceptable salt or ester thereof and an SGLT2 inhibitor or a pharmaceutically acceptable salt or es...
|
|
WO/2023/169456A1 |
This disclosure relates to GLP-1 agonists, pharmaceutical compositions, and methods of use thereof.
|
|
WO/2023/166005A1 |
The present invention relates to the field of organic synthesis and more specifically it concerns a process for preparing compound of formula (I) from a compound of formula (II). The process to prepare compound of formula (II) and the co...
|
|
WO/2023/164219A1 |
A method of producing a polymer includes steps of providing δ-valerolactone 2-ethylidene-6-hepten-5-olide (EVL); providing an amine-containing compound; allowing the EVL and the amine-containing compound to be mixed to form a mixture; a...
|
|
WO/2023/160672A1 |
The present disclosure provides LPA antagonists of formula I, as well as pharmaceutical compositions comprising the compounds disclosed herein. Also provided are methods for treating LPA-associated diseases, disorders, and conditions.
|
|
WO/2023/159303A1 |
Provided herein are Myc-Max inhibitory compounds having the structure of Formula I or Formula II and compositions thereof for use in the treatment of cancer. In particular, the Myc- Max inhibitory compounds may be useful for the treatmen...
|
|
WO/2023/145804A1 |
The purpose of the present invention is to provide a novel B0AT1 inhibitor. The present invention relates to a compound represented by formula (I): (the symbols in the formula are as described in the description) or a salt thereof. The p...
|
|
WO/2022/187490A9 |
Provided herein are methods of ring-opening polymerization of lactones to yield bioderived polyesters with varying backbone structures.
|
|
WO/2023/138695A1 |
The present invention relates to a cathepsin K inhibitor having a structure as shown in formula (0) and/or formula (II), wherein cyanopyrimidine or a ketone serving as an electrophilic group is a key group to exert a good inhibition effe...
|
|
WO/2023/139207A1 |
The invention pertains to a process for processing a crude lactide comprising the steps of: separating a crude lactide stream comprising L-lactide, D-lactide, and meso-lactide in one or more steps to form a meso-lactide stream comprising...
|
|
WO/2023/141534A1 |
Disclosed herein are agents that target telomerase reverse transcriptase (TERT) for treating cancer and sensitizing cancer cells to genotoxic therapy. The methods include inhibiting induction of an immunosuppressive factor in a subject i...
|
|
WO/2023/127809A1 |
In the production of agricultural and horticultural crops, etc., damages caused by pest insects, etc. are still significant, and, therefore, the development of novel pest control agents has been required due to factors such as the emerge...
|
|
WO/2023/127533A1 |
The purpose of the present invention is to provide a production method of 2-methyl-5,6-dihydro-2H-pyran, by which a high yield can be achieved even in the case of reacting at a relatively low temperature and in which the adhesion of prec...
|
|
WO/2023/116804A1 |
The present disclosure relates to a lipid compound and a lipid nanoparticle composition. Specifically, the present disclosure relates to a lipid compound, which can be used in combination with other lipid components, such as neutral lipi...
|
|
WO/2023/118968A2 |
Disclosed herein are methods of detecting xanthine oxidase expression in polycystic kidney disease, or methods of delaying the onset or treating polycystic kidney disease, or both. The inventors have made the remarkable discovery that ab...
|
|
WO/2023/115054A1 |
This application relates to methods of inhibiting the growth of human pathogenic bacteria in or on a plant by treating the seeds of the plant with an aqueous solution containing one or more ascarosides. The application also provides a me...
|
|
WO/2023/109057A1 |
Provided in the present invention is an S-configuration pro-xylane crystal form compound, which is a crystalline hydrate, and has a molecular formula of C8H16O5·H2O. Compared with the prior art, the S-configuration pro-xylane crystal fo...
|
|
WO/2023/115002A1 |
The present disclosure relates to compound Formula (I) methods for making the compounds and methods for their use.
|
|
WO/2023/114818A1 |
The disclosure relates to compounds of Formula (I), which are RXFP1 receptor agonists, compositions containing them, and methods of using them, for example, in the treatment of heart failure, fibrotic diseases, and related diseases such ...
|
|
WO/2023/110394A1 |
The present invention is directed to a process for C-H insertion by the gem-hydrogenation of an internal alkyne.
|
|
WO/2023/114229A1 |
The present disclosure provides compounds, compositions containing such compounds, and methods of designing, developing, producing and preparing compounds represented by general Formula (I), including pharmaceutically acceptable salts th...
|
|
WO/2023/114819A1 |
The disclosure relates to compounds of Formula (I), which are RXFP1 receptor agonists, compositions containing them, and methods of using them, for example, in the treatment of heart failure, fibrotic diseases, and related diseases such ...
|
|
WO/2023/109877A1 |
The present invention provides Pro-Xylane, a production method therefor, and the use thereof in cosmetics. The Pro-Xylane has a content of C-β-D-xylopyranoside-2-hydroxypropane of 95% or more, and contains C-β-D-xylopyranoside-2-(S)-hy...
|
|
WO/2023/104201A1 |
An aryl C-glucoside derivative, a preparation method therefor and the use thereof. Specifically provided are an aryl C-glucoside derivative as shown in formula I, a tautomer thereof, a stereoisomer thereof, a prodrug thereof, or a pharma...
|
|
WO/2023/102652A1 |
The present application provides compounds which are attachable to skin, in particular hydrogenated genipin compounds and de-glycosylated oleuropein compounds, which are useful, for example, as colorants and sunscreens.
|
|
WO/2023/097678A1 |
A method for synthesizing (R)-5-(2,2-dimethyl-4H-benzo[d][1,3]dioxin-6-yl)oxazolidin-2
-one. The synthesis route of the method is: where X is Br, Cl or I, preferably Br. Preferably, chiral phenyloxazolidin-2-one is prepared from a 2-brom...
|
|
WO/2023/094830A1 |
Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof wherein Ring A, Ring B, R1, R2, R3 and L are as defined herein. The compounds are antagonists of the resistant (R-type) voltage-gated calcium ion ch...
|
|
WO/2023/089522A1 |
Disclosed herein are compounds of Formula (I), Formula (III) or Formula (IIIa), or pharmaceutically acceptable salts thereof, wherein A, L, X1, X2, a, b, R1 and R2 are as defined herein. Also disclosed are lipid nanoparticles comprising ...
|
|
WO/2023/082429A1 |
The present invention relates to a synthesis method for a polysubstituted 3-hydroxy-2-pyrone. The method comprises the following steps: S1, subjecting a compound of formula (I) to an Achmatowicz rearrangement reaction to obtain a compoun...
|
|
WO/2023/080243A1 |
One purpose of the present invention is to provide a novel thioester derivative and a method for producing the same, a novel ketone derivative and a method for producing the same, a novel method for producing a C-arylhydroxyglucoside der...
|
|
WO/2023/076626A1 |
The disclosure relates to compounds of Formula (I), which are RXFP1 receptor agonists, compositions containing them, and methods of using them, for example, in the treatment of heart failure, fibrotic diseases, and related diseases such ...
|
|
WO/2023/070009A1 |
The invention relates to silyl ether derivatives of certain polyether polymers, and methods of making the same, compositions comprising the same, and methods of using the same. The polyether polymers precursors of said derivatives includ...
|
|
WO/2023/067132A1 |
A compound of general formula (I), wherein X takes various meanings, for use in the treatment of cancer.
|
|
WO/2023/052616A1 |
The invention relates to sugar amides and mixtures thereof as well as their use incosmetic or household applications and oil or mining applications.
|
|
WO/2023/051749A1 |
The present invention relates to an AAK1 inhibitor and the use thereof. Specifically, the present invention relates to a compound as represented by formula I, a tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt o...
|
|
WO/2023/051133A1 |
The present invention relates to a spiro compound and the use thereof. The spiro compound has the structure as shown in formula (1). The material provided in the present invention has the advantages of a high optical and electrical stabi...
|
|
WO/2023/051684A1 |
A bacterial capsular oligosaccharide derivative, a preparation method therefor, a pharmaceutical composition and a use thereof. The derivative is as shown in formula (I), and the substituent is described in detail in the description. The...
|
|
WO/2023/054626A1 |
Provided is a cyclopropanamide derivative. A compound represented by formula (1) [wherein: n represents an integer of 0, 1, 2 or 3; ring A represents (1) 4-pyridyl which may be substituted with 1 to 4 substituents, or (2) phenyl which is...
|
|
WO/2023/051657A1 |
Provided are a compound as represented by formula I, and a racemate, an enantiomer, a diastereomer and a pharmaceutically acceptable salt thereof, and the use thereof in the prevention or treatment of related diseases caused by coronavir...
|
|
WO/2023/040101A1 |
The present invention belongs to the technical field of organic synthesis, and provides a method for preparing δ-valerolactone. Compared with a method in the prior art for preparing δ-valerolactone by means of reacting, under an alkali...
|
|
WO/2023/043038A1 |
The present invention provides a novel compound for a capping layer, and an organic light-emitting device comprising same.
|
|
WO/2023/036945A1 |
The invention relates to a compound of formula (I) wherein A is NH or CH2; G1 is a linear or a cyclic alkyl; Y1 is CH or N; Y2 is O, N or CH, W is O, N or CH; Z is NH or O; X1 and X2 and R, and R1 to R8 are functional groups.
|
|
WO/2023/029928A1 |
An amino lipid and an application thereof: using ethenesulfonyl fluoride (ESF), a dual-function electrophile, to build an amine head group and a hydrophobic chain into an amino lipid, fully utilizing the click chemical reaction propertie...
|
|
WO/2023/032797A1 |
The present invention provides: an actinic ray sensitive or radiation sensitive resin composition containing a resin that undergoes decomposition through the action of an acid and gains a larger polarity, and a compound represented by a ...
|
|
WO/2023/022040A1 |
Provided is a radiation-sensitive composition comprising a polymer having a structural unit represented by formula (1) and a photodegradable base. In formula (1), R1 represents a hydrogen atom, a fluorine atom, a methyl group or the like...
|
|
WO/2023/022050A1 |
A compound represented by general formula (16) or a pharmaceutically acceptable salt thereof. (In general formula (16), R1 to R3 each independently represent a hydrogen atom or an optionally substituted C1-C12 alkyl group, R4 and R5 each...
|
|
WO/2023/017269A1 |
The invention relates to compounds of formula (I) and to their use in treating or preventing an inflammatory disease or a disease associated with an undesirable immune response: (I) wherein RA and RB are as defined herein.
|
|
WO/2023/011668A1 |
Disclosed in the present invention are a perinaphthenone compound and the use thereof. The compound can bind to E3 ubiquitin ligase tripartite motif 25 (TRIM25), thereby facilitating the recognition of TRIM25 to a pathogen and inducing p...
|
|
WO/2023/009610A1 |
The application discloses methods useful for the synthesis of racemic, scalemic, and chiral alpha-tocotrienol quinone, including synthetic intermediates and methods for making said synthetic intermediates.
|
|
WO/2023/284645A1 |
Disclosed in the present invention are an amide compound and a use thereof. The structure of the compound is as shown in general formula I; see the description for the definitions of substituents in the formula; and the use of the compou...
|
